Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement: A randomized clinical trial

Nicolaas E. Deutz, Eric M. Matheson, Laura E. Matarese, Menghua Luo, Geraldine E. Baggs, Jeffrey L. Nelson, Refaat A. Hegazi, Kelly A. Tappenden, Thomas R. Ziegler, NOURISH Study Group

Research output: Contribution to journalArticlepeer-review


Background: Hospitalized, malnourished older adults have a high risk of readmission and mortality. Objective: Evaluation of a high-protein oral nutritional supplement (HP-HMB) containing beta-hydroxy-beta-methylbutyrate on postdischarge outcomes of nonelective readmission and mortality in malnourished, hospitalized older adults. Design: Multicenter, randomized, placebo-controlled, double-blind trial. Setting: Inpatient and posthospital discharge. Patients: Older (≥65 years), malnourished (Subjective Global Assessment [SGA] class B or C) adults hospitalized for congestive heart failure, acute myocardial infarction, pneumonia, or chronic obstructive pulmonary disease. Interventions: Standard-of-care plus HP-HMB (n = 328) or a placebo supplement (n = 324), 2 servings/day. Measurements: Primary composite endpoint was 90-day postdischarge incidence of death or nonelective readmission. Other endpoints included 30- and 60-day postdischarge incidence of death or readmission, length of stay (LOS), SGA class, body weight, and activities of daily living (ADL). Results: The primary composite endpoint was similar between HP-HMB (26.8%) and placebo (31.1%). No between-group differences were observed for 90-day readmission rate, but 90-day mortality was significantly lower with HP-HMB relative to placebo (4.8% vs. 9.7%; relative risk 0.49, 95% confidence interval [CI], 0.27 to 0.90; p = 0.018). The number-needed-to-treat to prevent 1 death was 20.3 (95% CI: 10.9, 121.4). Compared with placebo, HP-HMB resulted in improved odds of better nutritional status (SGA class, OR, 2.04, 95% CI: 1.28, 3.25, p = 0.009) at day 90, and an increase in body weight at day 30 (p = 0.035). LOS and ADL were similar between treatments. Limitations: Limited generalizability; patients represent a selected hospitalized population. Conclusions: Although no effects were observed for the primary composite endpoint, compared with placebo HP-HMB decreased mortality and improved indices of nutritional status during the 90-day observation period. Clinical trial registration: NCT01626742.

Original languageEnglish (US)
Pages (from-to)18-26
Number of pages9
JournalClinical Nutrition
Issue number1
StatePublished - Feb 1 2016


  • High-protein beta-hydroxy-beta-methylbutyrate
  • Hospitalization
  • Lean body mass
  • Malnourished
  • NOURISH study
  • Oral nutritional supplement

ASJC Scopus subject areas

  • Nutrition and Dietetics
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement: A randomized clinical trial'. Together they form a unique fingerprint.

Cite this